Program Information
4DCBCT-Based Dose Assessment for SBRT Lung Cancer Treatment
W Cai1,3*, M Hurwitz1,3, C Williams1,3, S Dhou1,3, R Berbeco1,3, J Seco2,3, F Cifter1,3, M Myronakis1,3 , J Lewis1,3, (1) Brigham and Women's Hospital, Boston, MA, (2) Massachusetts General Hospital, Boston, MA, (3) Harvard Medical School, Boston, MA
Presentations
WE-D-303-4 (Wednesday, July 15, 2015) 11:00 AM - 12:15 PM Room: 303
Purpose: To develop a 4DCBCT-based dose assessment method for calculating actual delivered dose for patients with significant respiratory motion during the course of SBRT or anatomical changes between treatment days.
Methods: To address the limitation of 4DCT-based dose assessment, we propose to calculate the delivered dose using time varying (‘fluoroscopic’) 3D patient images generated from a 4DCBCT-based motion model. The method includes four steps: (1) before each treatment, 4DCBCT data is acquired with the patient in treatment position, based on which a patient-specific motion model is created using a principal components analysis (PCA) algorithm. (2) During treatment, 2D time-varying kV projection images are continuously acquired, from which time-varying ‘fluoroscopic’ 3D images of the patient are reconstructed using the motion model. (3) Lateral truncation artifacts are corrected using planning 4DCT images. (4) the 3D dose distribution is computed for each timepoint in the set of 3D fluoroscopic images, from which the total effective 3D delivered dose is calculated by accumulating deformed dose distributions. This approach is validated using six modified XCAT phantoms with lung tumors and different respiratory motions derived from patient data. The estimated doses are compared to that calculated using ground-truth XCAT phantoms.
Results: For each XCAT phantom, the delivered tumor dose values generally follow the same trend as that of the ground truth and at most timepoints the difference is less than 5%. For the overall delivered dose, the normalized error of calculated 3D dose distribution is generally less than 3% and the tumor D95 error is less than 1.5%.
Conclusions: XCAT phantom studies indicate the potential of the proposed method to accurately estimate 3D tumor dose distributions for SBRT lung treatment based on 4DCBCT imaging and motion modeling. Further research is necessary to investigate its performance for clinical patients data.
Contact Email: